Cambium Bio (ASX:CMB) Short Percentage of Float


ASX:CMB Cambium Bio Ltd ASX:CMB
34 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:CMB vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Cambium Bio's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Short Percentage of Float falls into.


ASX:CMB
34GF Score
Cambium Bio Ltd ASX:CMB
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
34GF Score

Get the complete analysis for ASX:CMB

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price